Back to top
more

Antares Pharma, Inc. (ATRS)

(Delayed Data from NSDQ)

$3.04 USD

3.04
1,289,259

+0.06 (2.01%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.04 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Holdings' (ASRT) Q1 earnings call, investors will focus on the sales performance of its marketed products.

Halozyme (HALO) to Acquire Antares for Auto Injector Platform

by Zacks Equity Research

Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.

Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?

by Zacks Equity Research

Antares Pharma (ATRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Antares Pharma (ATRS) delivered earnings and revenue surprises of 100% and 5.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SmileDirectClub (SDC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

SmileDirectClub (SDC) delivered earnings and revenue surprises of 10.71% and 1.95%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

West Pharmaceutical Services (WST) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 6.25% and 3.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Henry Schein (HSIC) delivered earnings and revenue surprises of 18.89% and 4.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of 3.25% and 1.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Antares Pharma (ATRS) Q3 Earnings Match Estimates

by Zacks Equity Research

Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and -0.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Antares Pharma (ATRS) Reports Next Week: What to Expect

by Zacks Equity Research

Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Antares Pharma (ATRS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Antares Pharma (ATRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Antares Pharma (ATRS) Meets Q1 Earnings Estimates

by Zacks Equity Research

Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 2.98%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Antares Pharma (ATRS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Antares Pharma (ATRS) Q4 Earnings Lag Estimates

by Zacks Equity Research

Antares Pharma (ATRS) delivered earnings and revenue surprises of -25.00% and 7.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Antares Pharma (ATRS) Q3 Earnings Match Estimates

by Zacks Equity Research

Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 10.84%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Antares Pharma (ATRS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study

by Zacks Equity Research

Shares of AMAG (AMAG) decline almost 17% after the company's pregnancy drug, Makena fails in the post approval PROLONG study.

Teva (TEVA) Launches First Generic Version of Mylan's EpiPen

by Zacks Equity Research

Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.

AMAG Pharmaceuticals Focuses on Product Development & Buyouts

by Zacks Equity Research

We issued an updated report on AMAG Pharmaceuticals, Inc. (AMAG) on Jul 4.

    AMAG Down Despite Positive Data on Makena Auto-Injector

    by Zacks Equity Research

    AMAG Pharmaceuticals (AMAG) announced positive top-line results from its pharmacokinetic (PK) study on Makena, subcutaneous auto-injector.